{"@id":"https://bioecon.ru/technology/cell-free-dna-sequencing/","@type":"Technology","cluster":"diagnostics-medtech","formats":{"html":"https://bioecon.ru/technology/cell-free-dna-sequencing/","json":"https://bioecon.ru/api/v1/technology/cell-free-dna-sequencing/index.json"},"id":"cell-free-dna-sequencing","industries":["diagnostics"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/diagnostics/"],"suppliers":["https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/mgi/","https://bioecon.ru/companies/paris-biofoundry-france/","https://bioecon.ru/companies/eversyn-gmbh/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/cell-agritech/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/cryoport-systems/"]},"maturity":null,"name":"Секвенирование бесклеточной ДНК","regions":["us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-09-18","entity":"natera","kind":"vendor","urls":["https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx","https://investor.natera.com/news/news-details/2026/Natera-Reports-First-Quarter-2026-Financial-Results/default.aspx","https://investor.natera.com/news/news-details/2026/Signatera-CDx-Approved-by-the-FDA-as-a-Companion-Diagnostic-in-Muscle-Invasive-Bladder-Cancer-MIBC/default.aspx","https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/","https://www.natera.com/company/news/natera-announces-ivdr-certification-for-signatera-across-multiple-cancers/","https://www.natera.com/company/news/natera-reports-second-quarter-2026-financial-results/","https://www.natera.com/company/news/nccn-recommends-ctdna-mrd-testing-using-signatera-technology-in-landmark-bladder-cancer-guideline-update/","https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm"]},{"date":"2026-09-18","entity":"guardant-health","kind":"vendor","urls":["https://investors.guardanthealth.com/press-releases/press-releases/2020/Guardant-Health-Guardant360-CDx-First-FDA-Approved-Liquid-Biopsy-for-Comprehensive-Tumor-Mutation-Profiling-Across-All-Solid-Cancers/default.aspx","https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx","https://investors.guardanthealth.com/press-releases/press-releases/2026/FDA-Approves-New-Guardant360-Liquid-CDx-the-Largest-FDA-Approved-Liquid-Biopsy-Panel-with-a-100x-Expanded-Footprint/default.aspx","https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-Second-Quarter-2026-Financial-Results-and-Increases-2026-Revenue-Guidance/default.aspx","https://www.businesswire.com/news/home/20260219448137/en/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Outlook","https://www.medicaldevice-network.com/news/fda-approves-guardant-health-next-generation-liquid-biopsy-panel/","https://www.sdbj.com/news/enews/guardant-health-scaling-san-diego/","https://www.sec.gov/Archives/edgar/data/1576280/000119312526187423/d68529dars.pdf"]}],"stages":[{"n":1,"title":"Стабилизированный забор крови"},{"n":2,"title":"Выделение плазмы"},{"n":3,"title":"Экстракция и пробоподготовка библиотек"},{"n":4,"title":"Секвенирование с коррекцией ошибок"},{"n":5,"title":"Коллинг вариантов"},{"n":6,"title":"Клинический отчёт"}],"summary":"Секвенирование фрагментарной бесклеточной ДНК из крови — пренатальный скрининг, наблюдение минимальной остаточной болезни и жидкая биопсия для выбора терапии, движимые коррекцией ошибок на всё более глубоких пределах обнаружения. В таблице два поставщика с полностью прослеженными досье; остальное поле ждёт досье с полной прослеженностью фактов.","url":"/technology/cell-free-dna-sequencing/","verified":"2026-09-18"}